A new and improved method for preparing maxacalcitol and an intermediate therefor is provided. The method is an efficient and cost-effective process for preparing maxacalcitol and an intermediate therefor.

The present invention relates to a new process of production of menaquinone 4, which is also known as vitamin K2.

The present invention relates to a new process of production of menaquinone 4, which is also known as vitamin K2.

The present invention relates to a new process of production of menaquinone 4, which is also known as vitamin K2.

The invention relates to an improved process for isomerizing polyunsaturated non-aromatic compounds including acyclic conjugated polyenes and alicyclic conjugated polyenes. In particular it relates to an improved and safe process for forming a 11-E retinoid compounds in high yield by expending as few energy as possible and with avoiding at most possible side products or product mixtures. This is achieved by feeding at least one of retinoid compounds of formula 2 to 5, or at least one of retinoid compounds of formula 2 to 5 and retinoid compound of formula 1, an organic solvent and a photosensitizer into a reaction device and irradiating the thus obtained reaction mixture with visible monochromatic light, at least 90% of the power of said monochromatic light and at most 100% of said power being emitted in the range from 460 nm to 580 nm.

The invention relates to an improved process for isomerizing polyunsaturated non-aromatic compounds including acyclic conjugated polyenes and alicyclic conjugated polyenes. In particular it relates to an improved and safe process for forming a 11-E retinoid compounds in high yield by expending as few energy as possible and with avoiding at most possible side products or product mixtures. This is achieved by feeding at least one of retinoid compounds of formula 2 to 5, or at least one of retinoid compounds of formula 2 to 5 and retinoid compound of formula 1, an organic solvent and a photosensitizer into a reaction device and irradiating the thus obtained reaction mixture with visible monochromatic light, at least 90% of the power of said monochromatic light and at most 100% of said power being emitted in the range from 460 nm to 580 nm.

A method for preparing an NMR material, comprising generating parahydrogen in gas or liquid form at a first location; transporting the parahydrogen away from the first location; mixing a precursor compound including a metabolite component with a catalyst for hydrogenation; hydrogenating the precursor compound using the parahydrogen; transferring polarization in the precursor compound to a nuclear spin of the metabolite component; cleaving a side arm of the precursor compound in a chemical reaction, with the metabolite molecule being one of the products of the reaction; separating the metabolite molecule from the catalyst for hydrogenation and other products of the reaction; and generating metabolite molecules for use in an MRI scanner by extracting a sample of the metabolite molecule having at least 5% polarization.

A method for preparing an NMR material, comprising generating parahydrogen in gas or liquid form at a first location; transporting the parahydrogen away from the first location; mixing a precursor compound including a metabolite component with a catalyst for hydrogenation; hydrogenating the precursor compound using the parahydrogen; transferring polarization in the precursor compound to a nuclear spin of the metabolite component; cleaving a side arm of the precursor compound in a chemical reaction, with the metabolite molecule being one of the products of the reaction; separating the metabolite molecule from the catalyst for hydrogenation and other products of the reaction; and generating metabolite molecules for use in an MRI scanner by extracting a sample of the metabolite molecule having at least 5% polarization.

A compound, composition, or method for treating cancer is disclosed. The compound (that can be used in the composition and/or method) can include

##STR00001##

or pharmaceutically acceptable salts or solvates thereof. R.sup.1a-R.sup.1d, R.sup.2-R.sup.3 (and R.sup.4 where applicable), and A---B can be as defined herein.

A compound, composition, or method for treating cancer is disclosed. The compound (that can be used in the composition and/or method) can include

##STR00001##

or pharmaceutically acceptable salts or solvates thereof. R.sup.1a-R.sup.1d, R.sup.2-R.sup.3 (and R.sup.4 where applicable), and A---B can be as defined herein.